arteriosclerosis, glomerulosclerosis, and variable degrees [11, 12] . Therefore, the use of the terminology alloantigen-dependent versus alloantigen-independent is preferof interstitial inflammation, fibrosis, and tubular atrophy [1] . Not unique to the kidney, chronic allograft failure able. In this Forum, I will be mostly focusing on the role and mechanisms of indirect allorecognition in graft affects all solid organ allografts including the heart, lung and, to a lesser degree, the liver [1] . In fact, in other than rejection, particularly chronic rejection. liver transplant recipients in whom recurrent disease is Direct and indirect allorecognition a major problem, chronic allograft dysfunction is the major cause of graft loss after the first year post trans-
The primary initial event that ultimately leads to graft rejection is allorecognition (T-cell recognition of alloanplant. Several studies have established the clinical risk factors of chronic allograft failure. These factors include tigen), in particular, antigens of the major histocompatibility complex (MHC). Several other factors can contribdelayed graft function, acute rejection, infection (such as CMV), and "underimmunosuppression" with acute ute to the effector mechanisms of graft dysfunction and ultimately failure, however. Using gene knockout anirejection, particularly recurrent and late episodes (beyond three months) [2] [3] [4] . mals, Krieger et al showed that CD4ϩ T-cells are essential for initiating allograft rejection [13] . There are two Chronic allograft dysfunction is mediated by both alloantigen-dependent factors (recipient-donor incompatidistinct, yet not mutually exclusive, pathways of allorecognition by CD4ϩ T-cells [14] [15] [16] [17] [18] [19] . In the so-called "dibility, acute rejection, underimmunosuppression) as well as alloantigen-independent factors (ischemia, hypertenrect" pathway, T-cells recognize intact allo-MHC molecules on the surface of donor antigen-presenting cells sion, reduced nephron mass, hyperlipidemia, infection, drug nephrotoxicity) [2, 3, 5, 6]. The mechanisms through (APCs) (Fig. 2) . Peptides, derived from endogenous proteins including MHC molecules, bound into the groove which alloantigen-independent factors contribute to graft dysfunction have not yet been defined [6] . But it of the MHC play an important role in this mode of allorecognition [20] . In the so-called "indirect" pathway, is alloantigen-dependent mechanisms that predominate in initiating and propagating the injury that leads to T-cells recognize processed alloantigen presented as peptides by self APCs (Fig. 2) . The basic premise for indirect chronic allograft loss. Perhaps the best evidence supporting a dominant role for alloantigen-dependent factors is allorecognition as a mechanism for initiation and/or amplification of allograft rejection is that donor alloantigens the clinical observation that the half-life (defined as the time when 50% of grafts have failed after surviving the are shed from the graft, taken up by recipient APCs, and presented to T-cells. The findings in humans [21, 22] first year) of renal allografts decreases with decreasing degrees of HLA matching, that is, incompatibility, in and in mice [23] that at least some of the peptides eluted from cell surface class-II MHC molecules represent MHC living-related as well as in cadaveric grafts [7] . In addition, patients who demonstrate donor-specific hyporeacsequences suggest that processing of MHC molecules is a physiologic event in vivo. tivity exhibit a very low incidence of chronic rejection [8] . Experimental evidence from re-transplantation studies Although no evidence has indicated that T-cells recognizing alloantigens via the direct versus indirect pathway in rat models of chronic allograft rejection confirms the importance of alloantigen-dependent mechanisms, parare predetermined to be biologically different, from the standpoint of contribution to mechanisms of allograft ticularly in initiating the chronic rejection process [9] . Furthermore, data from several experimental animal rejection, these two pathways of allorecognition are distinct for the following reasons: first, differences exist models clearly indicate that induction of donor-specific tolerance prevents development of chronic rejection [10] .
in the microenvironment and locale of "professional" (bone-marrow-derived) APCs (donor versus self) at difTherefore, this discussion will focus on alloantigen-dependent mechanisms of allograft dysfunction, particularly ferent times after transplantation; second, direct responses can be primary or primed (secondary) T-cell the role of indirect allorecognition mechanisms. In that regard it is important to clarify some poorly defined termiresponses, while indirect responses are all primed (secondary) T-cell responses; third, there can be different nology that has been used in the literature. "Chronic allograft dysfunction" is a generic term that does not imply effects of immunosuppressive or tolerance regimens on primary versus primed T-cell responses. Therefore, dicausation. "Chronic rejection," on the other hand, implies an alloimmune-mediated process driven by the host reacrect and indirect allorecognition need not be mutually exclusive pathways, as each is mediated by different sets tion against graft antigens. "Immunologic" versus "nonimmunologic" mechanisms have been used interchangeof T-cell clones, and both can be involved in the rejection process simultaneously or at different times post transably with "alloantigen-dependent" versus "-independent" mechanisms, respectively, although this terminology is plantation. Mounting evidence indicates that indirect allorecognition, analogous to self-restricted T-cell recognition not entirely accurate, as several alloantigen-independent factors mediate injury through inflammatory mechaof nominal antigens, occurs during allograft rejection. I will return to this topic later. nisms that involve immune cells and/or their products The question is, what are the role and mechanisms of responses when challenged by the allopeptides, but more interestingly they also had significant DTH responses indirect allorecognition in rejection? Early acute allograft rejection might be mediated predominantly by the when challenged by allogeneic WF splenocytes, and not when challenged by syngeneic LEW or third-party allodirect pathway, as the graft contains a significant number of donor-derived passenger APCs (particularly dendritic geneic BN (RT1 n ) splenocytes. Follow-up studies on the immunogenicity of these synthetic class-II MHC allopepcells), which express a high density of MHC molecules and can provide the necessary co-stimulatory signals for tides confirm the occurrence of self-MHC-restricted T-cell recognition of processed allo-MHC peptides durfull T-cell activation [19] . Later, when grafts lack passenger (donor) APCS, T-cells primed by the indirect pathing vascularized cardiac as well as renal allograft rejection [32, 33] . Splenic CD4ϩ T-cells, taken from LEW way might play the dominant role in the process of chronic rejection [24] . Definitive evidence proving this recipients of WF vascularized cardiac or renal allografts, proliferate to specific class-II MHC peptides presented hypothesis is lacking, however. Braun et al have demonstrated that "directly" primed CD4ϩ T-cell lines/clones by responder APCs. Our studies also demonstrate that not all polymorphic peptides are immunogenic. In fact, could effect early acute rejection but not chronic rejection of passenger-cell-depleted renal allografts [25] Role and mechanisms of indirect allorecognition cules and rejected specific skin allografts in an accelerated fashion [30] . Both those studies suggest that selfElegant studies by Auchincloss et al, using class-II MHC-deficient mice as donors in a skin allograft model, restricted T-cell recognition of processed allo-MHC molecules plays a role in allograft rejection. The availability showed that indirect allorecognition by host CD4ϩ T-cells of donor class-I MHC antigens can initiate rapid of MHC sequences has allowed synthesis of MHCderived peptides for studying the role and mechanisms skin allograft rejection [41] , and that these cells can help generate cytotoxic T-lymphocytes against donor class-I of indirect allorecognition in graft rejection. Our initial studies focused on studying the immunogenicity of syn-MHC [42] . In a separate study, the same investigators showed that IgG alloantibody production is dependent thetic class-II MHC allopeptides in vivo [31] . Inbred LEW (RT 1 ) rats, used as responders, were immunized on CD4ϩ T-cells recognizing peptides of donor antigens through the indirect pathway [43] . Dalloul et al, also in the foot pad with a mixture of eight polymorphic synthetic (25mer) class-II MHC allopeptides. These seusing MHC knockout animals, showed that CD4ϩ T-cells can reject skin allografts through indirect allorecquences represent the full length of the hypervariable domains of RT1.B u (DQ and I-A like) and RT1.D u (DR ognition [44] . Taken together, these data strongly suggest that, in the absence of direct allorecognition, CD4ϩ and I-E like) ␤ chains of the WF (RT1 u ) rat. Responder T-cells harvested from popliteal and inguinal lymph T-cells primed by the indirect pathway can initiate allograft rejection, and that either class-I or class-II donor nodes of immunized animals exhibited significant proliferation to the MHC allopeptides in vitro when presented antigens can be recognized by CD4ϩ T-cells after processing and presentation by recipient class-II MHC moleby self APCs. In vivo, peptide-immunized LEW animals mounted significant delayed-type hypersensitivity (DTH) cules on self APCs. Studies with synthetic class-I MHC peptides derived ingly, in addition to the severe interstitial cellular rejection, animals primed with the immunogenic class-II from the DA rat strain showed that peptide-immunized LEW rats were capable of rejecting DA skin allografts MHC peptides had severe vascular rejection compared with control animals. Specifically, allografts harvested in an accelerated fashion [45] . Furthermore, peptideimmunized recipients rejected renal allografts depleted from immunogenic class-II MHC allopeptide-primed recipients showed classic morphologic features of vascular of donor-derived interstitial dendritic cells [46] . These findings clearly demonstrate that indirect allorecognition rejection with necrotizing arteritis, including fragmentation of the elastica, fibrinoid necrosis, and a mild pericontributes to the rejection of vascularized allografts.
Effector mechanisms of transplant rejection involve celladventitial mixed cellular infiltrate. Allografts from this group showed deposition of IgG (predominantly IgG2b), ular, delayed-type hypersensitivity (DTH) responses, cellmediated cytotoxicity, and humoral components [19, 47] .
C3, and fibrin throughout the vasculature. By contrast, acute rejection in unprimed rats was cellular in nature, Once fully activated, CD4ϩ T-helper cells produce cytokines that orchestrate various effector arms of the alloimwith normal vessels on histologic examination, and essentially no endothelial deposition of IgG, C3, or fibrin. mune response (Fig. 2) . Activated CD4ϩ T-cells provide help for CD8ϩ T-cells, B-cells, and monocytes by secreOur morphologic and immunohistologic data suggest an important role for alloantibodies in the accelerated vasting cytokines and by initiating cell-cell contact-dependent mechanisms. Activated monocytes release a variety cular rejection observed in animals primed with immunogenic donor class-II MHC allopeptides. of noxious agents that mediate tissue injury. B-cell alloantibody production ultimately results in complement and
We also examined the T-cell proliferative response to the peptides in primed and control animals. Interestingly, cell-mediated cytotoxicity. Activated CD8ϩ T-cells kill graft cells in an antigen-specific manner through direct we observed lymphocyte proliferation against peptides known to be immunogenic in both the peptide-immurecognition of class-I MHC molecules on target donor cells. Therefore, CD4ϩ T-cells activated via the indirect nized animals and in the animals primed in vivo by the transplanted organ, as previously described [32, 33] . Howpathway may effect allograft rejection by DTH and alloantibody-mediated mechanisms independent of direct alloever, the degree of proliferation to the peptides was significantly higher in the peptide-immunized group. Thus, recognition. First, we examined whether priming through the indirect pathway by immunization with donor-derived peptide immunization markedly increased the precursor frequency of allopeptide-reactive T-cells compared with MHC allopeptides could accelerate acute rejection in an experimental vascularized cardiac allograft model in the that seen in in-vivo priming as a result of rejecting a graft [48] . This increased precursor frequency might play rat [48] . We immunized LEW recipients of WF heterotopic cardiac allografts with a mixture of the immunoan essential role in initiating the effector mechanisms that accelerate the rejection process (Fig. 3) . genic (25mer) WF MHC class-II peptides (RT.1D u ␤1-25, RT1.D u ␤20-44, RT1.B u ␤1-25, and RT1.B u ␤20-44) in comTo study DTH mechanisms, we generated alloreactive T-cell clones by in-vivo priming via the indirect pathway plete Freund's adjuvant seven days before transplantation. The control group was immunized with adjuvant and [49] . Inbred LEW rats were primed in vivo by immunization in the foot pad with the immunogenic synthetic class-II saline or with a mixture of the nonimmunogenic peptides in adjuvant. The animals received cyclosporine, 5 mg daily MHC allopeptide (RT1.D u ␤, residues . This is the same peptide that alone is effective in priming animals for seven days; immunosuppression was discontinued thereafter. Animals immunized with the immunogenic to accelerate allograft rejection [48] . One week later, we harvested the primed lymphocytes from the draining peptides rejected their allografts in an accelerated fashion; animals immunized with the nonimmunogenic peplymph nodes, and established an RT1.D u ␤20-44 T-cell line by repeated stimulation with RT1.D u ␤20-44 peptide tides or adjuvant did not develop accelerated allograft rejection. No difference existed in the time course of the presented by responder APCs. The T-cell line proliferated significantly to the RT1.D u ␤20-44 peptide but not rejection process when recipients were challenged with third-party BN cardiac allografts, so we deduced that the to a specificity control peptide derived from the RT1.B locus (RT1.B u ␤20-44) when presented by self APCs. effect observed was a specific response to donor class-II MHC peptide priming. Additional studies showed that
In addition, the T-cell line produced significant amounts of IFN-␥ but not IL-4 upon restimulation with the priming with the immunogenic RT1.D u ␤ (HLA-DR-like) peptides, and specifically with the most immunogenic RT1.D u ␤20-44 peptide. By limiting dilution, we then generated T-cell clones from this Th1 line. Flow cytometric single peptide (RT1.D u ␤, residues 20-44), was responsible for the observed acceleration of the rejection process [48] .
analysis with specific monoclonal antibodies showed that all RT1.D u ␤20-44-specific T-cell clones were CD4ϩ. Six Morphologic evaluation of cardiac allografts harvested from animals at the time of rejection revealed interstitial clones proliferated specifically to the RT1.D u ␤20-44 peptide and produced IFN-␥ but not IL-4 when restimulated cellular rejection of significantly greater intensity in the accelerated compared with the control groups. Interestwith RT1.D u ␤20-44 peptide in vitro (that is, Th1 clones). Using RT-PCR transcript analysis with specific rat TCR repertoire: V␤ 4, 8.2, or 9. In comparison, the clones generated from T-cell lines of RT1.D u ␤20-44-immunized V␤ primers, we showed that all these clones expressed V␤ 9 TCR transcripts. These clones are self-restricted LEW rats all expressed TCR V␤ 9 only. . The exact reasons why a clone is not pathogenetic are unknown, but preliminary significant DTH response to re-challenge with irradiated allogeneic WF spleen cells, but not to syngeneic LEW studies suggest that pathogenicity is related to affinity of the particular TCR binding to the peptideϩMHC or third-party BN splenocytes. This was the first demonstration that MHC allopeptide-specific Th1 cell clones complex on APCs [50] . In summary, CD4ϩ T-cells primed by donor peptides transfer a DTH response. The specific response to WF cells indicates processing and presentation of allo-MHC via the indirect pathway help monocytes and B-cells to effect DTH responses and produce donor-specific alloby self APCs in vivo.
We recently focused our studies on generating T-cell antibodies, respectively. These cellular and humoral mechanisms contribute to graft rejection. It is also possiclones from animals primed in vivo by rejection of vascularized allografts, because this is the physiologic pathway ble that such CD4ϩ T-cells help activate CD8ϩ cytotoxic T-cells which, through direct allorecognition of class-I of priming to donor-derived peptides [50] . We generated self-restricted class-II MHC allopeptide-specific T-cell MHC-bearing donor cells, contribute to allograft destruction by cytotoxicity [40] . clones (to the same peptide, RT1.D u ␤20-44) from the spleen and kidney of LEW (RT1 1 ) rats undergoing acute Human studies rejection of MHC-incompatible WF (RT1 u ) renal allografts. All the clones that specifically proliferated to the The first report of self-restricted T-cell recognition of processed allo-MHC in humans was published by de peptide (RT1.D u ␤20-44) were CD4ϩ and produced IFN-␥ but not IL-4 upon restimulation with the peptide Koster et al, who produced T-cell clones primed by a synthetic peptide derived from the hypervariable domain in vitro. The Th1 clones from splenic and renal T-cell lines of rejecting animals expressed a restricted TCR V␤ of the ␤ chain of HLA-DR3 (residues 67-85) [51] . These activity, epitope spreading, and chronic rejection in huLessons learned from these in-vitro studies and in-vivo man cardiac allograft recipients. Utilizing synthetic pepanimal studies utilizing synthetic MHC peptides have tides corresponding to the hypervariable region of 32 been extended into the human transplant arena. Liu and HLA-DR alleles, they followed donor-specific MHC alcolleagues have demonstrated donor-specific MHC allolopeptide lymphocyte responses in a population of 34 peptide T-cell reactivity in humans with recurring epiheart allograft recipients. T-cells from sequential samsodes of acute cardiac allograft rejection [54] . More interesting was the demonstration of shifting T-cell responses ples of blood collected from the patients as long as 36 to different allopeptides with time. Such a change in the months after transplantation were studied in limiting pattern of T-cell responses has been termed epitope switchdilution analysis for allopeptide reactivity. The incidence ing or spreading and can occur to peptides representing of coronary artery vasculopathy was significantly higher alternative regions within a given MHC ␤ chain hypervain patients who displayed persistent alloreactivity late riable region (intramolecular spreading) or alternatively, after transplantation (after six months) than in patients to peptides representing different MHC chains (intermowho showed no alloreactivity after the first six months lecular spreading) [54] . An important observation in after transplantation. Epitope spreading was observed these human studies is that indirectly primed T-cells are with an increased frequency in patients developing vaspresent at a much lower precursor frequency than are culopathy in less than two years, compared with patients directly primed T-cells. In fact, Liu et al calculated that without vasculopathy [56] . These studies and our own such allopeptide-specific T-cells are present at 100 to observations in renal transplant recipients [55] indicate 1000 times lower frequency than that of cells recognizing that indirect allorecognition correlates with, and might intact (direct allorecognition) allo-MHC [24] . This findplay a key role in, chronic rejection. ing is consistent with the hypothesis that small numbers of peptide-primed T-cells are mediating an indolent im-SUMMARY mune response that reflects the natural history of chronic Taken together, these experimental observations in rejection, a phenomenon characterized by slowly proanimals as well as humans have led to the formulation gressive organ dysfunction.
of a hypothesis linking MHC-allopeptide-primed T-cells We then studied indirect allorecognition in human and chronic rejection (Fig. 4) . Small numbers of indirenal allograft recipients with chronic rejection [55] . We rectly primed T-cells are present and targeted against a found that peripheral blood lymphocytes from 82% of restricted repertoire of immunodominant peptides in the patients who were mismatched for at least one of 3 DR immediate post-transplant period. Concomitant with the molecules and who had chronic allograft dysfunction possible decline in the importance of directly primed specifically proliferated to the mismatched allopeptides T-cells with time post engraftment [40, 57] , the precursor (N ϭ 9/11). Proliferation was seen in only 6% of control frequency of indirectly primed T-cells continues to be subjects (2/33, P Ͻ 0.0001) ( Table 1 ). The precursor low grade. In addition, naïve CD4ϩ T-cells recognize frequency of peptide-specific T-cells was more than tennew epitopes, by a yet unclear mechanisms, and are confold higher in patients with chronic rejection as comtinuously becoming activated while immunosuppression pared with controls. These data demonstrated for the is being reduced. Activated CD4ϩ T-cells provide help first time that T-cells of patients with chronic graft dysand in turn activate the effector mechanism of allograft function are primed to recognize and respond to specific donor-derived MHC allopeptides [55] . Our study also destruction, namely, monocytes/macrophages (DTH), B-cells (alloantibodies), and endothelial and smooth musWe can draw several implications from this working hypothesis. First, to prevent chronic allograft rejection, cle cells. Through complex cellular and molecular mechanisms [58] , which include tissue injury, healing, and repair, we need to specifically target the indirect pathway. In addition, it is likely that such interventions will have to the grafts develop morphologic changes of chronic rejection that lead to clinical organ dysfunction and failure.
be introduced at a relatively early stage prior to epitope shifting. Several strategies hold promise in that regard. mune response for therapeutic purposes, it may have significant clinical relevance to several immune-mediIn particular, strategies targeted at blocking CD28-B7 and/or CD40L-CD40 T-cell co-stimulatory activation ated diseases. Dr. Madias: Since CTLA4 provides an inhibitory sighave been shown to prevent development [59] [60] [61] [62] [63] [64] and even interrupt progression [65] of chronic rejection in nal to activated T-cells, what about a strategy of blocking the B7-CD28 pathway but allowing the engagement of experimental animals. Interestingly, targeting T-cell costimulatory activation also might be effective in amelio-B7-CTLA4 or even enhancing the expression of CTLA4 inhibitory receptor on activated T-cells? rating injury mediated by alloantigen-independent mechanisms of graft dysfunction, such as ischemia/reperfusion Dr. Sayegh: This is a very important issue as well. If you target B7, then you are actually inhibiting both injury [11, 12] . Obviously, the applicability of these rodent studies needs to be confirmed in large animals [66] pathways, CD28 and CTLA4. In certain circumstances, delaying the administration of CTLA4Ig is more effecbefore clinical trials in humans are begun.
tive than giving it early on. Our hypothesis is that this delay allows CTLA4 to be expressed on T-cells. in various models. However, I'm not sure that you clearly Dr. Sayegh: I could hypothesize on potential mechadifferentiated its relative importance in acute versus nisms. One possibility, for example, is that acute rejecchronic rejection, although your presentation suggests tion, infections (such as CMV), or potentially ischemic that you favor the hypothesis that it might be a dominant injury to the graft can upregulate MHC expression. This and unsuppressed mechanism in chronic rejection. Would upregulation can lead to increased shedding of MHC you agree that the clinical data that you presented prove molecules, which in turn can result in a different type that the indirect mechanism of allorecognition occurs pattern of peptide reactivity because hidden epitopes are but doesn't discriminate whether this is important in now exposed. In addition, changes in immunosuppression acute versus chronic rejection? or other factors with time can affect T-cell recognition On a broader scope, it seems to me that acute and of different epitopes. The bottom line is that the precise chronic rejection clearly differ with regard to pathologic mechanisms of epitope spreading remain unknown.
patterns and the immune effector pathways, but is there Dr. Madias: It would appear that both the distribution any evidence that the initiation of the injury differs? Is and the timing of expression of the various costimulatory it possible that both direct and indirect allorecognition signals are of importance. What do we know about the occur in all phases of rejection? Does the separation of mechanism of expression of B7 molecules on activated acute and chronic rejection as clinical entities make any APCs and endothelium and of CTLA4 inhibitory recepdifference? tors on activated T-cells?
Dr. Sayegh: Yes, I do believe there is a difference. Dr. Sayegh: We know, for example, that cytokines There's a fundamental pathophysiologic difference that are important in controlling the upregulation of costimuwe don't understand very well and that is at least manilatory molecules. We recently published two studies in fested by the different morphology and pathology that which we looked at ischemic injury and its effect on B7 we see. Let me go back to the issue of the relative contriexpression [11, 12] . Both studies were in a setting in bution of each pathway. I do believe that both pathways which there was no alloimmune response. We found are operative in the acute setting. In fact, as I said before, that renal ischemic injury not only upregulates MHC available data support strongly the contribution of the expression but also upregulates B7 expression. When indirect pathway to acute rejection. But I favor the hywe gave animals with ischemic injury to their kidneys pothesis that in the acute setting, because of the high systemic CTLA4Ig, we ameliorated the ischemic repernumber of antigen-presenting cells in donor organs like fusion injury in the absence of an alloimmune response.
dendritic cells, which express high-density MHC and coWe think this decrease in reperfusion injury is because stimulatory molecules, the direct pathway is dominant. of inhibition of the cytokine/chemokine surge. Not a lot
We know at the precursor frequency levels that T-cells is known about what regulates CTLA4 upregulation.
responding via the direct allorecognition pathway are This is a very important area because if we can figure a much higher in number than those responding via the indirect pathway. In the chronic phase, the importance way to use a physiologic pathway to terminate the im-of the direct pathway is reduced. For example, we know (IL-4, IL-10). We are trying to simplify this method and generate what we call "mini" T-cell lines to develop new that the graft lacks donor APCs several weeks after transplantation. The endothelial cell can function as a immuno-surveillance assays of transplant patients. The answer to your second question is yes, there are ways direct APC, but some data from heart transplant patients showed that many patients with chronic rejection are to serially measure the degree of inhibition of the indirect pathway, but they are not very well developed. "tolerant" to the direct response, as suggested by the precursor frequency analysis against donor cells [57] .
Dr. Andrew J. King (Division of Nephrology, New England Medical Center): One strategy that has been Because these patients cannot mount a direct response, the chronic rejection that occurs must be driven by indiemployed over the years, and especially prior to the introduction of cyclosporine, was pre-transplant donor rect allorecognition.
At this moment, we cannot definitively answer the blood transfusion. There is evidence of a beneficial effect of this approach in preventing solid organ rejection, parquestion of what is the relative contribution of direct versus indirect alloresponses to acute versus chronic reticularly with one-haplotype-matched transfusion heart transplant recipients. Could you speculate on how this jection. My fundamental point is that a pathway exists that has been forgotten for years-indirect allorecognimight work in relation to your model? Could this practice in some way inhibit epitope shifting? tion-and that it probably plays a major role in chronic rejection. To exaggerate a bit for effect, I don't think Dr. Sayegh: It has been known for years that if you give donor antigen in the form of bone marrow or blood anybody cares substantially anymore about acute rejection; the major problem now is chronic rejection.
transfusion, you can induce tolerance in the recipient animal. The limited data in humans have not been reproDr. Madias: Is there cross-talk between the two pathways of allorecognition? Is it possible for recipient APCs ducible. The implication of our studies is that if one does not induce tolerance to the indirect response, prolonged to provide costimulation of T-cells that have been primed by the direct allorecognition pathway?
survival is likely, but the patient will probably end up developing chronic rejection. This also means that any Dr. Sayegh: Yes, this is called trans-costimulation. If the T-cell gets a costimulatory signal from the same APC, tolerance strategy that succeeds in preventing acute and chronic rejection has to induce tolerance to both direct it's called "costimulation in cis." The two pathways do talk to each other. The best demonstration of this is at and indirect responses. In recent studies, we showed that administration of donor antigen was necessary to induce the endothelial cell level. The endothelial cell is of donor origin, while the monocytes and T-cells are of recipient tolerance and prevent chronic rejection [70] . Dr. King: In your review of chronic rejection, you origin; they go through the endothelium to reach the graft. Indeed, recent data in collaboration with the laboreferred to the characteristic vascular lesion with intimal proliferation and an inflammatory response. What is the ratory of Dr. Briscoe at Children's Hospital in Boston show that endothelial cells can promote indirect allorecnature of the cells in that lesion? Are these T-cells with CD4ϩ markers? Are there CD8ϩ cells there? ognition [69] .
Dr. John T. Harrington (Dean, Tufts University Also, you implied that antibody production and B-cells play a role in this chronic rejection process. We have more data now that have not been published there are usually more monocytes/macrophages, and fewer CD4ϩ T-cells. The IgG antibodies play a very yet. In work similar to our rat studies, we generated T-cell lines and clones from patients. We took these important role; in fact, studies using the more refined ELISA assay show that you can correlate anti-donor cell lines from stable patients and those with chronic rejection. We found that in patients with chronic rejecIgG responses with the appearance of chronic rejection [71] . We think that this antibody response is a surrogate tion, the T-cell lines secrete TH1 cytokines (IL-2, IFN-␥). The stable patients, however, secrete TH2 cytokines for CD4ϩ indirect alloresponses, as previously shown [43] . immunogenicity of some of the peptides, you mentioned that a difference in only two amino acids led to a different Dr. Sayegh: The number of these patients was very small, and thus a firm conclusion cannot be drawn.
degree of immunogenicity. Do we know anything about the structure of those particular proteins and how that Dr. Kausz: You mentioned brain death as a possible cause of antigen-independent allograft dysfunction. Is minimal quantitative amino acid difference leads to such a powerful functional difference? there an immunologic mechanism behind that?
Dr. Sayegh: We recently published a paper on this Dr. Sayegh: We have gone beyond that and split the peptides into two peptides. Each one has only one amino issue [72] . We used a rat model of so-called "explosive" brain death. These animals developed shock and hypoacid difference, and you get the same immune response with one amino acid difference between donor and reciptension, hypoperfusion of the organs, and severe ischemic injury. The organs of these animals showed upregulaient [50] . That's not unusual because these are probably linear structures that are being recognized and bound to tion of inflammatory cytokines and chemokines within hours after the injury.
HLA molecules of the recipient APCs. What is being recognized as foreign is the substituted amino acid. The Dr. Bertrand L. Jaber (Division of Nephrology, New England Medical Center): If one assumes that alloantigen T-cell receptor thus needs only to encounter one polymorphic amino acid to mount an immune response. This cell-surface shedding is a prerequisite for indirect allorecognition, what are the factors that determine cellphenomenon has been shown in mutation studies. You can substitute only one amino acid in a molecule and surface shedding besides acute rejection?
Dr. Sayegh: This has not been studied. yet induce a vigorous immune response. This is not inconsistent at all. Dr. Jaber: It has been shown that many of the membrane-bound cytokine receptors are cleaved off the cell Dr. Madias: Could you please comment on the most promising strategies for induction and maintenance of surface to become soluble following activation of metalloproteinases. It would be interesting to examine whether tolerance and the potential mechanisms involved? Dr. Sayegh: There are several strategies to try to incell-surface shedding of alloantigens is indeed regulated by putative metalloproteinases. The possible modulation duce tolerance, but some of the clinically promising ones include blocking T-cell costimulation, donor bone marof this phenomenon by metalloproteinase inhibitors could lead to the development of new therapeutic straterow chimerism, donor-specific transfusions coupled with immunomodulatory strategies, and some humanized gies that limit indirect allorecognition.
Dr. Sayegh: Yes. In support of that hypothesis, we monoclonal antibodies [73] . The translation of these strategies from small animals in the laboratory to priknow through association studies that levels of soluble donor MHC molecules correlate with chronic rejection.
mates and humans remains an elusive goal. think that that maneuver is a useful strategy? If so, does the efficacy relate to increased immunosuppression?
